Correspondence  by unknown
dysfunction. Because such a cohort faced a very poor outcome,
offering a procedure that potentially had a 20% mortality rate was
(and still is) rational. Transplantation has a 5% mortality rate in
optimized patients and a 70% five-year survival rate (9). Timing of
surgical treatment is therefore based on specific knowledge of
natural history reflected by the presence of factors that precisely
define the prognosis.
Available current data do not point to equipoise between PLV
and heart transplantation, particularly because long-term results
are unknown. In addition, with ongoing refinements, medical
treatment of congestive heart failure complemented by implantable
LVADs has contributed to a plateau in the number of deaths of
patients waiting for a heart transplant in the U.S. (http.//
www.unos.org). This has been true for the past several years,
despite the increasing gap between the number of patients being
listed for heart transplants and the number of heart transplants
being performed.
This line of reasoning would indicate that with our present
knowledge, which is limited by long-term follow-up, a controlled
trial of PLV should be aimed at patients with congestive heart
failure who are at greatest risk of dying while waiting for an
available donor heart. Such patients stand to benefit the most from
such a therapy. The alternative arm of such a trial would be
maximal medical therapy, including inotropic agents, and implant-
able LVADs. One could then imagine a scenario in which the
possibility of entering such a trial would be presented to class IV
patients who are or about to reach status I and are also ideal
selected candidates for PLV (e.g., dilated cardiomyopathy with left
ventricular end-diastolic dimension .70 mm and preserved LV
wall thickness). Because patients in both arms of the trial would
remain listed for transplantation, follow-up would theoretically be
equal for both the LVAD and PLV group. Such a trial would also
provide the possibility for patients to cross over from the PLV
group to the LVAD group. At the other end of the spectrum,
another outcome of such a trial strategy would be for patients and
treating physicians in the PLV group to choose to prolong the
bridge period and avoid transplant surgery.
As long-term data regarding PLV become available, a more
precise trial could separate class III and IV patients into two
separate trials with different end points. Indeed, current knowledge
may not be developed enough to design the most meaningful
randomized trial possible.
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Is Electron Beam Computed Tomography the
Sole Detection Method for Coronary Calcium?
Budoff et al. (1) emphasized the advantages of electron beam
computed tomography (CT) over the currently used noninvasive
imaging exercise techniques to distinguish between ischemic and
nonischemic cardiomyopathy. However, other techniques that
noninvasively detect coronary calcification, fluoroscopy and spiral
CT have been used for the same purpose but were inexplicably
omitted from their discussion. This omission mistakenly creates
the impression to readers that electron beam CT is the sole
available technique. Twenty years ago, Johnson et al. (2) used
fluoroscopy for the diagnosis of the ischemic type of cardiomyop-
athy, a report that Hurst’s textbook of cardiology did not neglect to
mention (3). Spiral CT is another widely available alternative for
the detection of coronary calcium, which we have reported (4–8)
and which has been published by others (9). The new generation
of spiral techniques are based on the ability to scan the heart within
a single breathold, despite the lack of electrocardiographic trigger-
ing. The value of dual-slice spiral CT for the differentiation of
ischemic from nonischemic dilated cardiomyopathy was reported 3
years ago (4). Budoff et al. confirmed the results of this study and
reproduced them: The diagnosis of ischemic cardiomyopathy
based on the presence of calcium by spiral CT (total score .0)
yielded sensitivity, specificity and total accuracy rates of 100%, 92%
and 97%, respectively, compared with 99%, 83% and 92%, respec-
tively, in their study. The relatively reduced specificity found by
Budoff et al. is probably attributable to their definition of dilated
cardiomyopathy, which was based solely on a left ventricular
ejection fraction ,40%, regardless of the left ventricular end-
diastolic volume. The main clinical relevance of both studies is the
contribution of fast CT techniques to the noninvasive diagnosis of
cardiomyopathy of unknown etiology. In these patients, the
absence of coronary calcium indicates a nonischemic etiology and
can rule out the necessity for coronary angiography.
One would expect the original reports to be highlighted by
Budoff et al. to strengthen their findings. Instead, they mysteri-
ously chose to ignore them. Was this a mere oversight?
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REPLY
In differentiating the etiology of cardiomyopathies, the greatest
danger is mislabeling an ischemic (with subsequent revasculariza-
tion as a treatment option) as a nonischemic cardiomyopathy
(relegated to medical therapy or heart transplantation). Some
physicians even suggest that all patients with heart failure undergo
coronary angiography to exclude ischemia as an etiology. Although
routine angiography should not be implemented due to expense
and risk, there is a need for a highly sensitive test to discriminate
between these two conditions. The development of electron beam
computed tomography (EBCT) to detect coronary atherosclerosis
now provides clinicians with a noninvasive means to rule out
ischemic cardiomyopathy with 99% sensitivity (1).
With regard to evaluating coronary calcifications by other
means, chest radiography, fluoroscopy, conventional and spiral
computed tomography (CT) have each been reported (2). How-
ever, the decreased temporal and spatial resolution, slow acquisi-
tion time and inability to gate to the electrocardiogram (ECG)
limit the sensitivity of these modalities. There is evidence dating
back over 40 years that the presence of coronary calcification, as
detected by chest x-ray film or fluoroscopy, can identify patients
with advanced coronary artery disease. The sensitivity of fluoros-
copy in evaluating significant coronary artery disease ranged from
40% to 79% in seven large studies (3). Shemesh et al. (4) reported
coronary calcium imaging by double-helical CT, with accelerated
scan times, as having a sensitivity rate of 91% when compared with
angiographically significant coronary obstructive disease. However,
other preliminary data have shown that even at these accelerated
scan times, calcific deposits are blurred owing to cardiac motion,
and small calcifications may not be seen (5). The lack of ECG
gating will further limit the usefulness of these modalities. Because
sensitivity for obstructive disease is so important so as to not
misdiagnose an ischemic cardiomyopathy as nonischemic, tests
with higher sensitivities should be used when available.
Electron beam computed tomography, with its ability to acquire
images in 100 ms and gate to the ECG (to minimize coronary
motion), provides clinicians with a safe and noninvasive means to
detect and measure coronary calcium. The sensitivity of EBCT for
obstructive coronary artery disease is consistently above 95% and is
99% for multivessel disease in a large multicenter study (6). In the
study reported in JACC, (1), EBCT was demonstrated to exclude
ischemic cardiomyopathy noninvasively with a 98% negative pre-
dictive value.
Thus with regard to Shemesh, EBCT is not the only means to
evaluate coronary calcification. However, it does provide clinicians
with the most sensitive noninvasive means to discriminate between
ischemic and nonischemic cardiomyopathy.
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